POINT Biopharma Global Inc.
POINT Biopharma Global Inc. (PNT) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
pnt · stock forecast · 12 analysts (3M) · FMP · updated Apr 11, 2025
Analyst Rating & Consensus
Based on 12 Wall Street analysts in the past 3 months
Buy
12 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$17.00
Consensus
$13.75
+10.0% upside
Low
$10.00
Median: $14 · Last Close: $12.50
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$13.75
10.0% upside
High Target
$17
36.0%
Low Target
$10
-20.0%
Current Price
$12.50
as of today
Based on analyst price targets, the PNT stock price prediction for the next 12 months ranges from $10 to $17. The consensus PNT price forecast of $13.75 implies 10.0% upside from the current price of $12.50.
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $12.03 | ↓ 3.77% |
1-day model range: $11.98–$12.08. Peak: $12.08 (-3.77%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PNT · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-10-24 | Piper Sandler | Downgrade ↓ | Overweight→Neutral |
| 2023-10-06 | Raymond James | Downgrade ↓ | Outperform→Market Perform |
| 2023-10-05 | Raymond James | Downgrade ↓ | Outperform→Market Perform |
| 2023-10-04 | Truist Securities | Downgrade ↓ | Buy→Hold |
| 2023-10-04 | JonesTrading | Downgrade ↓ | Buy→Hold |
| 2023-10-03 | Truist Securities | Downgrade ↓ | Buy→Hold |
| 2023-10-03 | JonesTrading | Downgrade ↓ | Buy→Hold |
| 2023-05-16 | Oppenheimer | Maintains | Outperform→Outperform |
| 2023-05-15 | Oppenheimer | Maintains | Outperform→Outperform |
| 2022-12-14 | Raymond James | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on POINT Biopharma Global Inc. (PNT) stock. Of the recent 25 rating actions, 2 were upgrades and 7 were downgrades. 12 analysts currently cover PNT.
Analyst Recommendation Trends
PNT analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$241M
↑ 66.7% YoY
Revenue Next Year
$17M
↓ 93.1% YoY
EPS This Year
$0.95
EPS Next Year
$-1.12
↓ 217.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast PNT EPS of $0.95 for the current fiscal year, based on estimates from 5 analysts. The PNT revenue forecast is $241M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The PNT stock forecast is supported by two independent data sources: analyst consensus ratings from 12 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus PNT price target is $13.75 (+10.0% upside), with an analyst consensus of Buy.
The PNT short-term stock prediction for tomorrow is $12.03 (-3.77%).
POINT Biopharma Global Inc. trades on NASDAQ under the ticker PNT. The PNT stock outlook for 2027 is broadly positive, supported by a Buy consensus among 58% of covering analysts.
Frequently asked questions
PNT forecast · 8 questionsAccording to 12 Wall Street analysts, the average 12-month PNT price target is $13.75, with a high forecast of $17.00 and a low of $10.00. The median price target is shown in the chart above when available. This implies +10.0% potential upside from the current price of $12.50.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.